878376-02-4Relevant articles and documents
MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
-
Paragraph 00115; 00157, (2021/05/15)
The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pha
COMPOUNDS AND USES THEREOF
-
Page/Page column 325, (2020/10/20)
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
COMPOUNDS AND USES THEREOF
-
Page/Page column 317-318, (2019/10/15)
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors
Jung, Frédéric H.,Pasquet, Georges,Lambert-Van Der Brempt, Christine,Lohmann, Jean-Jacques M.,Warin, Nicolas,Renaud, Fabrice,Germain, Hervé,De Savi, Chris,Roberts, Nicola,Johnson, Trevor,Dousson, Cyril,Hill, George B.,Mortlock, Andrew A.,Heron, Nicola,Wilkinson, Robert W.,Wedge, Stephen R.,Heaton, Simon P.,Odedra, Rajesh,Keen, Nicholas J.,Green, Stephen,Brown, Elaine,Thompson, Katherine,Brightwell, Stephen
, p. 955 - 970 (2007/10/03)
The synthesis of a novel series of quinazolines substituted at C4 by five-membered ring aminoheterocycles is reported. Their in vitro structure-activity relationships versus Aurora A and B serine-threonine kinases is discussed. Our results demonstrate tha
